Alzheimer’s Disease, Cerebrovascular Disease, and the β–amyloid Cascade

Kie Honjo, Sandra E. Black, Nicolaas P.L.G. Verhoeff

ABSTRACT: Alzheimer’s disease (AD), considered the commonest neurodegenerative cause of dementia, is associated with hallmark pathologies including extracellular amyloid-β protein (Aβ) deposition in extracellular senile plaques and vessels, and intraneuronal tau deposition as neurofibrillary tangles. Although AD is usually categorized as neurodegeneration distinct from cerebrovascular disease (CVD), studies have shown strong links between AD and CVD. There is evidence that vascular risk factors and CVD may accelerate Aβ 40–42 production/ aggregation/deposition and contribute to the pathology and symptomatology of AD. Aβ deposited along vessels also causes cerebral amyloid angiopathy. Amyloid imaging allows in vivo detection of AD pathology, opening the way for prevention and early treatment, if disease-modifying therapies in the pipeline show safety and efficacy. In this review, we review the role of vascular factors and Aβ, underlining that vascular risk factor management may be important for AD prevention and treatment.

Alzheimer’s disease (AD) is one of the most important disorders causing dementia in the elderly, with an estimated 36 million people affected worldwide in 2010. The AD population is expected to rise to 66 million by 2030, and 115 million by 2050.1 Over 500,000 Canadians have dementia now, and over 100,000 develop some form of dementia each year. This exceeds the 40,000-50,000 new cases of stroke that occur in Canada each year. Estimates are, that by 2038, the annual incidence of new dementia cases per year in Canada will be 257,800, which is over double the current rate, and the prevalence will be 1,125,200 by 2038.2 In the USA, currently 5.3 million people have dementia,3 but this is expected to increase to 13.2 million by 2050.4 Currently, AD pathology contributes significantly approximately 60 per cent (50-75% range) of the total number of people with dementia living in developed countries. Moreover, in the USA, AD is the third most costly disease following cardiovascular disease and depression.5 Despite the large effort to understand the cause of this disease, its pathogenesis has still to be fully elucidated.

The first case of AD reported by Dr. Alois Alzheimer in 1906 revealed not only the presence of senile plaques and neurofibrillary tangles (NFT), but also the presence of cerebrovascular disease (CVD). Despite this seminal observation of concomitant CVD and the hallmark pathologies of AD in this important index case, Alzheimer himself and subsequent experts emphasized that plaques and tangles occurred in a presenile neurodegenerative disease distinct from CVD.6 Although the cognitive profile, mode of onset, and progression often differ in AD and vascular dementia (VaD), many studies have shown strong links between the two pathologies. A number of studies have shown that the risk factors for CVD are quite similar to those for non-genetic AD7,8, and that symptoms of dementia are more readily expressed when Alzheimer’s brain pathology coexists with cerebrovascular lesions.9–12 It has been also shown that cerebral infarction and other types of brain injury can accelerate Alzheimer neuropathology.13–15 Furthermore, amyloid-β protein (Aβ)


Correspondence to: Kie Honjo, 1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima, Japan 734-8551. Email: kiehon@hotmail.com.

It has been increasingly accepted that AD is linked to Aβ accumulation and NFT formation, which begins at a very early stage of disease progression in the brain of AD patients, often decades before clinical symptoms begin, and also that Aβ deposition can be present even though clinical dementia is not manifest. Hence, it has been thought that Aβ accumulation might be one of the earliest changes in the normal aging human brain. Recent basic research, however, provides evidence that Aβ in oligomeric form is neurotoxic, even when it has not fibrillated and deposited as plaques in the brain. As Aβ deposition is known to occur in the preclinical stage of AD, preclinical detection in vivo of AD is an important goal if amyloid-reducing drugs become available.

Recently, diagnostic criteria for Alzheimer’s disease have been updated and include Aβ imaging. Much effort has been made to develop sensitive and specific neuroimaging techniques to assist in the diagnosis of AD, but so far, no definitive criteria have been determined for diagnosing AD using conventional imaging modalities. Since AD has specific pathological characteristics in the postmortem brain, current imaging efforts are focused on direct imaging of the pathological process, especially of Aβ, in vivo. Positron emission tomography (PET) to detect Aβ deposition in the brain has been applied to normal elderly, prodromal AD as well as AD dementia populations.

These developments warrant a reconsideration of relationships among AD, CVD, and Aβ, especially since imaging methods may soon allow detection of amyloid as well as vascular brain injury in vivo. In particular, there is growing evidence that non-genetic AD may be initiated by vascular factors that precede and may foment the neurodegenerative cascade. We review some of the recently published basic and clinicopathological research data that support this hypothesis. We also review the pathogenesis of Aβ, and the opportunity that Aβ imaging offers for detecting preclinical AD. Our purpose is to give the neurological community an overview of basic and clinical research studies related to Aβ and AD, and to discuss vascular risk factors and the pathogenesis of AD with a special reference to the role of CVD in the emergence of AD dementia. Clinical implications of Aβ imaging for early detection of AD are also discussed.

**Definition**

Dementia has been generally defined as acquired persistent impairments in two or more cognitive domains (one of which should be memory for typical AD), sufficient to cause decline in ability to carry out social or occupational functioning independently. The most prevalent types of dementia are classified by presumed etiology into VaD caused by vascular lesions and AD resulting from a neurodegenerative process. According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and the previously widely used criteria formulated and recently revised by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorder Association (NINDs-ADRDA), which have just recently been revised in 2011, a demented individual who has evidence of substantial CVD previously is excluded from the diagnosis of probable AD. By DSM-IV-TR, this person would be automatically classified as VaD instead. Other research criteria specify imaging and clinical criteria including mode of onset and progression for VaD. However, CVD (for example, lacunar infaracts, CAA, microbleeds, and white matter changes) is frequently found in the brains of AD patients. The recent revision of the NINDs-ADRDA acknowledge that CVD is common and if concommitant CVD is evident, the designation of possible AD can be used.

Some researchers have hypothesized that there are two major pathological pathways leading to development of AD: the amyloid cascade or vascular injury. The first step of the amyloid hypothesis is excessive mis cleavage of amyloid precursor protein (APP) into longer fragments Aβ 40-42, which are neurotoxic and prone to fibrillate and deposit in senile plaques or along vessels, eventually leading to AD dementia. On the other hand, the vascular hypothesis suggests that ischemic changes and hy perfusion associated with aging and vascular risk factors, disturbing blood supply and metabolism, lead to neuronal and/or neuroglial energy failure which not only causes injury, but also accelerates amyloid over-production and reduces clearance, eventually leading to AD pathology. We will consider the evidence that has been put forward to support the pathogenic role of vascular injury in AD.

**Epidemiology**

Numerous prospective and retrospective population-based epidemiological studies have revealed a number of risk factors associated with both AD and CVD. These include cerebrovascular and cardiovascular risk factors, such as hypercholesterolemia, hypertension, hyperhomocysteinemia, atherosclerosis, diabetes mellitus, coronary artery disease, atrial fibrillation, high fibrinogen levels, high serum viscosity, smoking, and obesity. Ischemic stroke and transient ischemic attacks are also considered to be risk factors for AD. Related to those factors, age is also clearly one of the most important risk factors for AD. The incidence of AD is strongly and positively correlated with age, from less than 1% in people aged 65 years to over 25% in those who are aged 85 years or over in the Canadian Longitudinal Study on Aging. One meta-analysis revealed that prevalence of AD consistently doubles every 5.1 years after age 60, confirming the strong relationship between prevalence of AD and age.

Other predisposing factors include alcoholism, traumatic brain injury (TBI), aluminium toxicity, and herpes simplex virus infection, which are believed to cause inflammation and free radical damage to neuronal and other cells and subsequent glrosis. Significant TBI is also associated with overproduction of Aβ in the acute phase. Genetic polymorphism for apolipoprotein E type 4 (APOE-ε4) is the strongest genetic susceptibility risk factor for late-onset AD so far recognized, though recent studies have identified weaker genetic factors such as polymorphisms in the SORL1 gene for late onset AD as well as several other gene loci. Since the APOE-ε4 allele has been reported to be a risk factor causing various cerebrovascular and cardiovascular events, it is of great importance to better understand the role of this gene in the pathogenesis of AD in association with CVD. There are also gene mutations (e.g., PS1 on chromosome 14,
PS2 on chromosome 1, and APP on chromosome 21) for familial forms of early onset AD and for autosomal dominant CAA.

**Evidence of risk factors for AD and CVD (Figure 1)**

**a) Risk factors**

**Aging**

Aging is one of the most important factors causing various types of vascular events. Blood vessels and their basement membrane, endothelial and muscular components gradually lose their integrity with aging. Older adults who have no typical risk factors, such as genetic predisposition, vascular risk factors, or previous TBI, can still develop AD. In this particular patient group, aging likely plays a predominant role in AD pathogenesis. The normally aging brain undergoes pathophysiological changes, including decreased cerebral blood flow and glucose metabolism, which might, at least in part, result from loss of integrity of brain microvessels, both on the arteriolar and venular side of the microcirculation. Epidemiological studies have shown that the incidences of both AD and CVD increase with aging and some even claim that very late onset disease is part of the normal aging process. Therefore, the pathophysiological changes induced by aging could be etiologically related to, or even play an initiating role in, the pathogenesis of AD.

**Apolipoprotein E (APOE for gene; apoE for protein)**

Apolipoprotein E (apoE) is a plasma protein that transports lipids (e.g. cholesterol) and is associated with neuronal repair. The APOE gene, located on chromosome 19, has three allelic variations, and the occurrence rates in the general population are 8% for ε2, 78% for ε3, and 14% for ε4, although this varies in different populations. The APOE-ε4 allele is a genetic risk factor for both familial and sporadic late-onset AD; this has been confirmed epidemiologically and pathologically. Heterozygous APOE-ε4 carriers (ε2/ε4 or ε3/ε4) have 3-4 times the risk of developing AD, and homozygous carriers (ε4/ε4) have 10-12 times the risk. Patients with amnestic mild cognitive impairment (MCI) possessing at least one APOE-ε4 allele are at increased risk for developing AD.

**Figure 1:** The schema shows the hypothetical pathway of Alzheimer’s disease (AD). The main stream of this pathway is starting from the brain of individuals with no AD-related gene, i.e. sporadic AD, with mid-life vascular risk factors (hypercholesterolemia, diabetes mellitus, hyperhomocysteinemia, hypertension, smoking, obesity) through infarction (or hypoperfusion) and β-amyloid peptide (Aβ) increase, resulting in neuritic plaques or cerebral amyloid angiopathy (CAA), and finally progressing to clinical AD. There is another pathway that starts from the brain of individuals with AD-related genes such as having a mutation in presenilin1, presenilin2, or amyloid precursor protein (APP) genes, or Down’s syndrome. Sporadic AD is one of the most important disorders for the older population. Studies have suggested an association between risk factors and subsequent development of AD. However, some of the AD patients who do not have any risk factors may be affected by other aging effects that cause hypoperfusion in their brains. Once Aβ peptide levels increase in the brain, these might (possibly via tau elevation) cause mild cognitive impairment (MCI) or AD. However, the pathway from Aβ increases in to diffuse plaques may not cause dementia in older adults.
allele have a 62% increased risk of progressing to AD. In comparison to non-carriers, they have lower mini mental status examination (MMSE) and higher (worse) Alzheimer Disease Assessment Scale-Cognitive (ADAS-cog) scores, and smaller hippocampal sizes. Most longitudinal analyses of non-demented individuals also reveal a greater decline in performance on a variety of cognitive tests in APOE-ε4 positive subjects, showing that the presence of APOE-ε4 is a risk factor for cognitive impairment. As pathological evidence, the ApoE protein is present in senile plaques and binds to the Aβ(1–28) peptide. ApoE may have specific effects on the formation, aggregability, or clearance of Aβ, neurite outgrowth, and antioxidant activity. APOE-ε4 is neurotoxic compared to ε3, whereas ε2 has protective effects. Increased risk for AD, decreased age of onset, increased senile plaque density, and decreased cholinergic neuron density, have all been shown to correlate with APOE-ε4 allele copy numbers. APOE-ε4 is also reported to be a risk factor for CVD including CAA. APOE-ε4 was more common, not only in patients with AD (50-65%), but also in VaD (26%), than in non-demented controls (14%). This allele is a risk factor for developing CAA and cerebrovascular pathology associated with AD, and is associated with the presence of CAA-related hemorrhages that are probably due to increased Aβ deposition in the cerebral vessel walls. Although the APOE-ε2 allele is protective for AD, APOE-ε2 is believed to be a risk factor for CAA-related hemorrhages independent of AD, whereas APOE-ε4 is a risk factor dependent on concomitant AD.

The APOE-ε4 allele is associated with elevations in total cholesterol levels and atherosclerosis relative to the ε3 allele, while the ε2 allele has the opposite effect. ApoE is the major cholesterol carrier in the brain, is very important in repairing damaged neuronal membranes, and binds to Aβ. It has been thought that interactions of ApoE and cholesterol might play a role in Aβ secretion. Overall, APOE-ε4 may make the brain more vulnerable; it could be one of the most important genetic risk factors for brain damage, such as by CVD and AD. For a comprehensive review of the role of APOE in AD, please see the article by Kim et al.

Hypercholesterolemia

Hypercholesterolemia has received enormous attention because of its important etiological role in cardiovascular disease and therapeutic advances for its control. Epidemiological evidence has shown that hypercholesterolemia is also an important risk factor for AD. In the Rotterdam Study, high dietary intake of total fat and saturated fat increased the risk of dementia and AD, whereas fish consumption, a source of omega-3 polyunsaturated fatty acids, was inversely related to the incidence of dementia, particularly AD. This study also found that there was no relationship between serum cholesterol level and risk of dementia within two years, while a longitudinal population-based study showed that mid-life hypercholesterolemia was associated with increased risk of late-life MCI and AD. Another study showed that hypercholesterolemia correlates with the presence of Aβ deposition in the diffuse type of senile plaques, among subjects 40 to 55 years old. These epidemiological data are further supported by basic research studies suggesting that cholesterol may contribute to the development of AD pathology by altering APP processing. Simons et al showed in their in vitro studies that cholesterol level modulates the enzymatic processing of APP and Aβ production. Moreover, in APP transgenic mice, diet-induced hypercholesterolemia accelerated Aβ pathology and decreased APPτα, a product of the non-amyloidogenic pathway. Cerebral Aβ deposition occurred in APP transgenic mice on both atherogenic and normal diets, but only atherogenic diets impaired learning task performance. Hypercholesterolemia also increased the level of C-terminal fragments, the substrates for the subsequent intramembranous cleavage by the γ-secretase complex, resulting in an increase in Aβ 34, 38, 40, and 42 production. Low cholesterol favors the non-amyloidogenic cleavage of APP by α-secretase and leads to decreased Aβ generation, whereas high cholesterol favors β/γ-secretase activity and thereby increases Aβ production. The cholesterol transporter ABCA1 (ATP-binding cassette transporter) has become a focus of research, as it may connect cholesterol, ApoE, and Aβ. Lack of ABCA1 causes extremely low brain ApoE which gets stuck in amyloid plaques, and these abnormal APOE particles promote amyloid deposition in APP transgenic mice. Increasing ABCA1 activity may promote Aβ clearance.

Statins, therapeutic agents for the treatment of hypercholesterolemia, reduce serum cholesterol levels by inhibiting the rate limiting enzyme of cholesterol synthesis, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. Retrospective clinical studies have reported that the prevalence of diagnosed AD in patients taking statins was significantly lower than in those not taking statins. Both simvastatin and lovastatin reduce intracellular and extracellular Aβ42 and Aβ40 levels in cultures of hippocampal neurons and of mixed cortical neurons, and high-dose simvastatin induces a strong reduction of cerebral Aβ42 and Aβ40 levels in the cerebrospinal fluid and brain of guinea pigs. Furthermore, statins probably have other effects that antagonize Aβ neurotoxicity, Aβ-induced vasoconstriction, and inflammation, working directly on the underlying pathology rather than through lipid-lowering effects. The FINRISK study showed that lipid-lowering treatment was related to decrease in dementia risk. A small randomized control trial (RCT) using atorvastatin 80mg/day for six months showed a significant positive effect on the ADAS-cog. However, two recent larger multicenter RCTs, one with atorvastatin 80mg/day for 13 months and the other with simvastatin for 18 months, failed to show any benefit over placebo. A clinical trial of high-dose atorvastatin after transient ischemic attack or mild stroke found that it reduces stroke risk. Hence, it may be that cholesterol lowering medications may have a preventative benefit prior to clinical onset of AD through stroke prevention and possible vasoprotective and anti-inflammatory effects. For a summary of cholesterol in AD, please see a review article by Shobab et al.

Hypertension

Hypertension is an established risk factor for stroke, coronary heart disease, and VaD. It is also evident that hypertension is associated with late-life cognitive impairment and increased amounts of senile plaques and NFTs. In a Swedish study, increased blood pressure at the age of 70 increased the risk of dementia between the ages of 80 and 85. A longitudinal...
prospective population-based study showed evidence of a relationship between hypertension and AD. In the Honolulu-Asia study, Japanese-American men with elevated mid-life blood pressure had a higher risk for AD at a follow-up period of 25 years. A postmortem analysis of this Honolulu-Asia study showed that elevated systolic blood pressure (>160mmHg) in mid-life was associated with low brain weight at death and greater numbers of neuritic plaques in neocortex and hippocampus, while elevated diastolic blood pressure (>95mmHg) was associated with greater numbers of NFT in the hippocampus. There is evidence that antihypertensive drugs, such as calcium channel antagonists and angiotensin converting enzyme inhibitors (ACEI), may have some protective effects against development of dementia. A calcium channel antagonist was shown in an uncontrolled hypertensive population to reduce the emergence of dementia. Brain penetrating ACEI were found to reduce progression of cognitive decline in mild to moderate AD in one randomized control trial (RCT). However, ACEI failed to show a significant outcome in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial and in the Study on Cognition and Prognosis in the Elderly (SCOPE). Together, the data regarding the effectiveness of ACEI on cognitive decline in AD are inconclusive. One study shows that angiotensin AT1 receptor blockers (ARBs) are associated with lower risk of admission to a nursing home and death, and reduction in the incidence and progression of AD and dementia compared with ACEI. There is emerging evidence that ARBs may be more neuroprotective than ACEI because brain ACE also catalyzes cognition-enhancing brain peptides, amyloid peptides and converts toxic Aβ42 into less toxic Aβ40. The ARBs increase AT2 receptor activation, angiotensin II and IV, respectively. AT2 receptor activation is important for both learning acquisition and recall of passive avoidance behavior, whereas AT1 is critical only for retrieval, by which the greater cognition-enhancing effects of ARBs can be explained. One of the ARBs, valsartan, has been shown to prevent the formation of high molecular weight oligomeric Aβ peptides in vivo, and is the only antihypertensive drug that shows evidence of prevention in vivo of AD pathological processes at present. Another study suggested that antihypertensive treatment, which was mainly based on use of beta-blockers, diuretics, or both, might reduce the risk of dementia. Subjects with combined high systolic blood pressure and high total cholesterol level at midlife had a significantly increased risk for MCI and AD, indicating that these are risk factors for both CVD and AD. Diabetes mellitus is another risk factor for AD, as well as for each of the vascular factors listed above (hypercholesterolemia, hypertension, and diabetes mellitus), and also increases the risk of CVD. In an 18 year follow-up study, baseline body mass index (BMI) was higher among subjects who developed AD than those who did not become demented. Obesity also increased the risk of AD in a community-based cohort of the Cache County study, and of dementia in a Swedish population-based twin study. Metabolic syndrome is characterized by the clustering of abdominal obesity, hypertriglyceridemia, low level of high-density lipoprotein (HDL) cholesterol, hypertension, and hyperglycemia. Metabolic syndrome is associated with an increase of diabetes mellitus and cardiovascular disease, both of which are linked to CVD and AD. As mentioned above, the combination of hypertension and hypercholesterolemia increased the risk of AD. Similarly, subjects with the metabolic syndrome have an increased risk of developing AD. Hyperhomocysteinemia Elevated plasma homocysteine has emerged as another vascular risk factor for both CVD and AD, and can be a marker for low B12 or folate deficiency, though it can be elevated even when folate and B12 levels are within normal limits. It has been associated with an increased risk of atherosclerotic sequelae, including cardiovascular disease, carotid atherosclerosis, and stroke. Hyperhomocysteinemia has also been related to cerebral microangiopathy, endothelial injury and dysfunction, impaired nitric oxide activity, and increased oxidative stress. In cross-sectional and population-based cohort studies, elevated plasma homocysteine has been strongly associated with poor cognition, dementia, and development of AD. In those studies, the patients who developed dementia or AD had lower folate and vitamin B12 levels and higher homocysteine concentrations than the control subjects. This risk factor can, in part, be modificable by supplementation of folic acid, vitamin B12 and vitamin B6, but so far no prospective studies have verified efficacy in stroke or dementia prevention. For a through overview, please see Garcia’s review articles.
**Tobacco smoking**

The possible relationship between cigarette smoking and AD is a controversial issue. Smoking has been well known to be an important risk factor for cardiovascular disease, and the Rotterdam Study showed that smoking resulted in a more than twofold increased risk of AD.61 However, some epidemiologic studies have reported a consistently inverse relationship between smoking and the incidence of AD.115 One community based study shows that current smoking is associated with increased risk of incident AD but no increase for former smokers.116 These results were supported by other studies showing that chronic exposure to nicotine may protect against Aβ pathology: acute and chronic nicotine administration has improved cognitive performance of not only healthy humans but also of patients with AD.117,118 Possible protective effects of nicotine against Aβ accumulation in the brain post mortem, in vitro and ex vivo have been reviewed elsewhere.119 Presumably, smoking has two opposing effects on the brain: protective effects through nicotinic receptor stimulation, and pathologic effects on cerebral blood vessels. Also, the conflicting epidemiological results may represent a survival effect due to smokers dying prematurely, before they can express dementia.

There are a number of other vascular risk factors implicated in AD and Vascular cognitive impairment. Each factor is worthy of a full paper in itself, which is not possible in this overview. However, it is worthwhile to briefly summarize our current understanding of the associations and possible mechanisms for each of those factors.120-122

**b) Role of vascular risk factors**

**Atherosclerosis, Arteriosclerosis, and Cardiovascular disease**

Atherosclerosis and arteriosclerosis may be keys in the association of CVD and AD. An autopsy study showed that atherosclerosis in the circle of Willis and its corresponding leptomeningeal arteries was significantly more severe in AD patients compared to a non-demented elderly group.123,124 Honig et al also showed that the presence of large-vessel CVD or atherosclerosis is strongly associated with an increased frequency of neuritic plaques. Moreover, this association persisted regardless of the presence or absence of cerebral infarction.125 In a large population study, severe atherosclerosis confirmed by ultrasound was associated with a high incidence of AD.126 A probable pathophysiological consequence associated with extensive and increasing stenosis in the circle of Willis or other large cerebral blood vessels is hypoperfusion. A study in transgenic mice also showed that the lesion area affected by aortic atherosclerosis is positively correlated with cerebral Aβ deposition.66 Atherosclerotic cerebrovascular pathology itself might directly influence Aβ deposition and the development of AD through a variety of mechanisms, i.e., subclinical ischemia, distal atheromicroembolization, increased parenchymal oxidative stress, and blood pressure dysregulation, which might affect the blood-brain barrier (BBB) through which Aβ may be transported from blood into brain tissue and vice versa.56 Cardiovascular diseases are a risk factor in the same way as result of atherosclerosis, and cardiac disease itself might result in CVD such as cardioembolism caused by atrial fibrillation. There is even recent evidence for impaired transmirtal flow efficiency in diastolic filling on echocardiography in AD patients.127 Finally, a recent novel mechanism has been suggested by a study showing that tortuosity of the carotid artery termination, which anatomically abuts the substantia innominata where the cholinergic neurons are located, is increased in AD and is associated with a smaller volume of the substantia innominata and poor executive function.128

**Cerebral ischemia, hypoperfusion**

As a result of atherosclerosis and/or arteriosclerosis, cerebral ischemia or hypoperfusion occurs in patients who have vascular risk factors. Indeed, Snowdon et al. revealed that atherosclerosis of the circle of Willis was strongly associated with lacunar infarction, and those with the infarctions had poor cognitive function and a higher prevalence of dementia.12

Autopsy series have shown that 60-90% of AD cases exhibit various types of so-called silent cerebrovascular pathology including CAA, microvascular degeneration, and periventricular white matter (WM) lesions. Furthermore, a third of AD subjects show evidence of cerebral infarction at autopsy.9 The Nun study showed strong evidence that dementia is worse when both neuropathological features of AD and VaD coexist. White matter hyperintensities, which are thought to represent cerebral small-vessel disease revealed by magnetic resonance imaging (MRI), are detected more frequently and occupy more WM volume in AD patients than in normal controls.129 The dilatation of periarterial spaces in the white matter in AD is greater in frequency and severity than in controls, and correlates with Aβ load in the cortex and with the severity of CAA.130 Even in demented subjects who did not fully meet the neuropathologic criteria for AD, the severity of cognitive impairment or dementia is strongly correlated with the severity of brain infarction, and less AD pathology was needed with coexisting infarction to cause clinical dementia.12 Imaging-autopsy correlation studies suggest that periventricular WM disease may in fact be due to venous collagensis exacerbating chronic periventricular hypoperfusion, and blood-brain barrier leakage, resulting in a chronic venous insufficiency syndrome.131,132 The Honolulu-Asia Aging Study showed that the frequency of dementia increased with neuritic plaque density, and increased further in case of the presence of cerebrovascular lesions.13 Similarly, Esiri et al. showed that AD patients with additional CVD suffer significant reductions in cognitive examination scores, which can be seen even in patients with very mild pathological changes and normal or marginally reduced cognitive examination scores.10,133 CAA in AD patients also showed a significant correlation with dementia severity.134 These studies suggest that strokes or cerebrovascular events worsen cognitive impairment and functional outcome in patients diagnosed with AD.

Experimental animal studies have indicated that brain ischemia or hypoperfusion appear to increase presence of Aβ1-40 and 1-42, and APP expression.13 Microglial activation, inflammation, and vulnerability to subsequent brain ischemia are also enhanced in transgenic mice.66,135 In a rodent model of stroke, intraventricular Aβ (25–35) injections interfere with infarct healing with expanding size instead of shrinkage.136 This would have strong implications for stroke recovery in AD patients. To better explore the relationship between pure brain ischemia and Aβ appearance, some studies have been done using
non-transgenic rats to avoid the genetic effect on Aβ genesis. APP and Aβ appeared in the lesion as a result of induced ischemia, but disappeared during long-term observation. Moreover, even if the brain was saturated with Aβ1-42 by injection after brain ischemia, it resulted in widespread diffuse amyloid plaques in hippocampus and cerebral cortex, and neuronal, glial, ependymal, endothelial and pericyte cell bodies were observed to be filled with Aβ1-42 at the acute phase; however, no deposition of Aβ was observed after one year. Taken together, although brain ischemia does not result in permanent Aβ deposits, it induces Aβ production, which might have toxic effects on synapses in the hippocampus and elsewhere, causing memory loss and other cognitive problems.

**Reactive oxygen species (ROS), Inflammation, and Gliosis**

Reactive oxygen species (ROS) or superoxide is well known to be generated in the normal aging process, and as a consequence of ischemia. Reactive oxygen species gradually accumulate in the aging brain, damaging cell components, such as proteins, lipids, and DNA. If ischemia/reperfusion occurs, massive ROS and superoxide are generated, causing considerable damage in the brain. The amount of oxidized DNA base pairs was higher in leukocytes of patients with AD or MCI. NADPH oxidase, which causes ROS production in cerebral vessels, could be a mediator of the cerebrovascular dysregulation induced by aging, hypertension, and AD. Animal studies have shown that decreased Superoxide dismutase-1 (SOD1), an enzyme that reduces the amount of potentially harmful free radicals, resulted in increased vascular damage after cerebral ischemia. In contrast, no endothelial dysfunction was found if SOD1 was overexpressed in APP transgenic mice. Hence, SOD1 might have a protective key role, not only against ischemic insults, but also against the toxic endothelial effects of APP. Reactive oxygen species appear to be very valuable in the aging and AD brain, and are currently targets for intervention.

Chronic inflammatory features such as activated microglia, reactive astrocytes, and other markers of inflammatory processes, including complement factors and cytokines, and acute-phase proteins, such as alpha-1 antichymotrypsin frequently colocalize with Aβ or β-amyloid precursor protein (β-APP) in cerebral ischemia and AD. Both Aβ1-40 and Aβ are enhanced in reactive astrocytes, which appear in a similar distribution to AD pathologically, as seen in the hippocampus or CA1 and CA4 regions. Besides, Aβ itself enhances pathological and inflammatory responses, and Aβ toxicity enhances gliosis. Finally, both these basic research studies, and epidemiological studies have shown that anti-inflammatory drugs may slow the progression of AD though no prospective trials have confirmed these findings. In contrast, some recent studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) have not been able to reduce the incidence of AAD or dementia, and may have adverse effects, with increased incidence of dementia, AD, and neurtic plaques in a cohort of heavy NSAID users.

According to the evidence described above, risk factors related to AD might result in Aβ cleavage change or decrease in Aβ clearance from the brain tissue, and cause Aβ accumulation in the cells or the extracellular tissue in the brain. One study indicated that Aβ is rapidly produced and cleared from the CNS in human. Recently, a study suggested that Aβ1-40 and 1-42 clearance from the brain is more important than Aβ production in late onset AD cases. Acceleration of Aβ production and impaired clearance, induced not by gene mutation but by environmental factors surrounding brain cells, could contribute to the development of clinical AD.

**Acetylcholine (ACh) in relation to AD**

The cholinergic deficit in AD may not only involve cholinergic innervation of cortical neurons but also lead to a loss of cholinergic innervation of cortical blood vessels. This vascular cholinergic deficit may cause cerebral hypoperfusion, which contributes to cognitive decline and neurodegeneration. Because cholinotoxicity, most likely related to toxic Aβ assemblies, is responsible for the axonal, hippocampal and cortical ACh denervation. ACh deficiency appearing in the AD brain is a key issue contributing to the initial symptoms and to subsequent disease progression.

The characteristics of cerebral blood flow (CBF) and glucose metabolism in the AD brain are evident in a very early stage of the disease process. However, it is not clear from the literature which occurs earlier, glucose hypometabolism or hypoperfusion. One PET study found an increased oxygen extraction fraction in the parietotemporal cortices in AD; however, the vascular transit time and vascular reactivity were well preserved in AD patients, whereas those indices showed marked worsening in VaD patients. It is possible that vascular factors contribute in the pathogenesis of AD at the capillary level such that vascular changes and insufficiency may occur before alteration in energy metabolism. By combining glucose PET, and single photon emission computed tomography imaging or arterial spin labelling MR, it may be possible to investigate these issues and detect CBF and brain glucose metabolism in the same patient to better understand the pathophysiological brain changes in preclinical stages of AD. In future research, it may be worthwhile to study CBF and glucose metabolism pre- and post-AD medications, such as acetylcholinesterase inhibitors, to demonstrate acute and chronic treatment differences in very early AD or MCI patients, and to see directly which changes occur earlier.

**Aβ – biological evidence for the role of Aβ 1-42 vasulotoxin and neurotoxin**

**a) Aβ processing**

Aβ plaques and neurofibrillary tangles are key pathological features of AD. Generally, the Aβ molecule is a peptide of 39 to 43 amino acids in vivo, although Aβ polypeptides have been prepared for experimental studies in vitro, and rarely larger sizes in vivo. Both Aβ1-40 and 1-42 are the main components of Aβ accumulation in the brain with Aβ1-42 being deposited in senile plaques in the brain parenchyma and Aβ1-40 being deposited in the perivascular spaces around cerebral arteries, causing CAA.

Aβ is derived from the transmembrane protein APP. There are two APP cleavage pathways: the non-amyloidogenic pathway and the amyloidogenic pathway (Figure 2). In the non-amyloidogenic pathway, APP is cleaved by α-secretase into
shorter fragments that do not contain Aβ, or tend to polymerase and therefore this pathway does not result in amyloid deposition in the brain. In the amyloidogenic pathway, APP is cleaved by β-secretase (β-amyloid cleaving enzyme - BACE), followed by γ-secretase cleavage. The BACE cleavage liberates β-APP that contains the Aβ peptides fragment, and γ-secretase cleavage liberates the Aβ 1-40 and 1-42 polypeptides (amyloidogenic) from β-APP. The Aβ peptides are toxic in oligomeric forms and have a tendency to form fibrils and to aggregate in the brain, eventually depositing as plaques or CAA. The gene responsible for APP is located on chromosome 21. Trisomy of chromosome 21 causes Down’s syndrome, a condition in which AD pathology is very common, with Aβ deposition seen in the brain, often by age 40, in a similar manner to late onset sporadic AD. One post-mortem study suggests that the Aβ deposition begins over a decade prior to the clinical symptoms of dementia in Down’s syndrome.157

Approximately 2% of the AD patients possess an autosomal dominant genetic background, known as early-onset familiar AD, as the onset is in the third to fourth decades. They have mutations in presenilin 1 (PS1), presenilin 2 (PS2), or APP genes with an extremely high penetrance rate. PS1 is an essential cofactor for γ-secretase activity158 and PS2 is the homologue of PS1. Therefore, these subgroups, including Down’s syndrome, have a strong genetic inclination toward the increased production of Aβ1−42, which appears to accelerate the pathogenic process of AD. The other group, which is much more prevalent in older adults, is known as late-onset sporadic AD. This group has no known Aβ-related genes directly related to Aβ production, but rather appears for various reasons, including the presence of the ApoE-ε4, to have difficulty with amyloid clearance.150

b) Aβ structure

Classification of Aβ (Table)

The Aβ conformation is classified into two subgroups: amorphous and fibrillar Aβ. Amorphous Aβ constitutes diffuse plaques, whereas fibrillar Aβ, which is a main component of neuritic plaques, is associated with neurotoxicity and neurodegeneration. Soluble and insoluble Aβ are the other conformational classification. Soluble Aβ includes amorphous Aβ (preamyloid) and insoluble Aβ consists of fibrillar Aβ. In vivo, soluble Aβ exists in blood plasma, CSF, and the extracellular and intracellular spaces, and insoluble Aβ mainly exists in the extracellular space in the brain.

Soluble and insoluble Aβ levels are both increased in the AD brain, but correlations between soluble Aβ levels and the degree of synaptic loss and cognitive impairment are stronger.159 However, there appears to be little correlation between the numbers of amyloid plaques and the degree of cognitive impairment.160 These findings suggest that soluble Aβ may initiate neurodegeneration and that Aβ plaques may not be the primary pathophysiology, but rather a reaction to or a result of Aβ accumulation, perhaps even as an epiphenomenon.

Basic studies showed that there are several different sizes of Aβ assemblies (Table). The basic peptide for all assemblies is the monomeric Aβ. Low molecular weight Aβ (LMW Aβ) is the minimum unit of Aβ assembly. Other molecules are formed by aggregation, called oligomeric Aβ, ADDLs (Aβ-derived diffuse ligands), protofibrils, and fibrils.19,161-163 These assemblies maintain equilibrium between monomers and protofibrils, but the final progress from protofibrils to fibrils appears to be an irreversible phenomenon.163 Aβ assemblies have the propensity to enlarge their size, especially once protofibrils have appeared, even when they are in equilibrium.17 Therefore, if
environmental conditions, such as pH, Aβ and electrolyte concentrations, temperature, and incubation time are appropriate, the Aβ aggregates become larger and more difficult to dissolve. Amorphous Aβ appears at lower peptide concentrations and fibrillar Aβ at higher concentrations, and there is a time-dependent relationship, i.e. longer times result in larger sizes.  

**Alpha-helix, β-sheet, and β-turn structures**

Conformations of monomers and dimers are mainly dominated by α-helices. These switch to β-sheet structures for oligomers. Teplow suggested that ADDLs are the smallest form of protofibrils and would be expected to display some β-sheet structures but not large amounts. Protofibril formation involves substantial conformational rearrangement, during which unstructured, α-helix, and β-strand elements transform into predominately β-sheet/β-turn structures. Finally, protofibrils conform to β-sheet structures in large amounts, and form Aβ fibrils, which are also composed of β-sheet structures. Fibrils and larger protofibrils β-sheet structures correlate with Aβ concentrations in vitro. Aβ fibrillogenesis is thought to be based on the β-sheet structure.  

Senile plaques are a form of Aβ accumulation, and along with intercellular deposits hyperphosphorylated tau forming neurofibrillary tangles, are some of the earliest pathological changes appearing before neuronal loss occurs in both the aging and the AD brain. Senile plaques have two histologically different forms, which are thought to impact on disease symptoms and progression, classified as diffuse plaques and neuritic (or dense core) plaques. Diffuse plaques consist of amorphous Aβ, lack the β-sheet structure, and are not surrounded by dystrophic neurites. Neuritic plaques consist of fibrillar Aβ. Diffuse plaques are seen in normal aging, whereas neuritic plaques are found mostly in patients with AD, but also in a small numbers in the normally aging brain. Therefore, it is very important to understand the role of both diffuse and neuritic plaques in neurotoxicity, neuronal death, and clinical symptoms. Since Aβ β-sheet content is related to insolubility and neurotoxicity, it has been thought that fibrillar Aβ is extremely important in initiating AD pathology and for disease progression, making it an appropriate target for prevention and disease modification.

**c) Aβ toxicity**

As indicated above, fibrillar Aβ, protofibrils, and oligomer Aβ have the conformation of a β-sheet structure, which is specifically detected by Congo red or Thioflavin T staining. Aβ oligomers disrupt synaptic plasticity in vivo at concentrations found in human brain and CSF. Neurotoxicity of Aβ molecules appears to be possible not only with large aggregates, but also in LMW Aβ, although it is not seen in monomers. Even though Congo red and Thioflavin T can detect oligomer Aβ and larger sizes, these dyes do not detect LMW Aβ assemblies (see Table). Taken together, the neurotoxicity of Aβ aggregation, through fibril formation, appears to lead to synaptic loss and eventually to neuronal death, correlating with memory impairment and other cognitive and neuropsychiatric symptoms. Aβ1-42 is thought to be a more pathogenic toxic peptide than Aβ1-40. Intermolecular parallel β-sheet structure and β-turn formation play a role in the aggregation and neurotoxicity of Aβ1-42, and the N- and C-terminal residues form intramolecular β-sheet structures which stabilize each molecule. In contrast, Aβ1-40 does not form intramolecular β-sheet structures at the end of the Aβ peptide residues. Therefore, Aβ1-42 may have more propensity to accumulation and fibrillogenesis. Since Aβ1-40 is less fibrillogenic, its solubility is greater than Aβ1-42, and it normally drains from the brain along perivascular spaces more easily. The ratio of Aβ1-40 to Aβ1-42 likely contributes to the variability of disease progression with less tendency to form plaques with a higher Aβ40:42 ratio. For example, in hereditary cerebral hemorrhage with amyloidosis, which shows fewer parenchymal Aβ deposits compared to AD, the Aβ 40:42 ratio is significantly higher than that in human AD postmortem brain tissue. In APP transgenic mice, a study showed that an elevated ratio of Aβ 40:42 favors the formation of CAA versus parenchymal plaques, and this is altered by ApoE-ε4.

![Table: The names of Aβ and those relationship between Aβ aggregation molecules and characteristics of size, structure, neurotoxicity in vitro, and Congo red staining](https://www.cambridge.org/core/terms)
Therefore, the Aβ 40:42 ratio may play an important role in where Aβ aggregation occurs.

Cerebral Amyloid Angiopathy (CAA)

Cerebral amyloid angiopathy is another pathological finding commonly seen in the AD brain, and is considered an important cause of intracerebral hemorrhage as well as ischemic stroke especially in the older population who do not have any CVD risk factors.54 Cerebral amyloid angiopathy involves deposition of fibrillar Aβ1-40 (Table) in cortical and leptomeningeal vessels, and is neuropathologically detected by Congo red staining. The prevalence of CAA is between 10-40% in people who are 61-70 years old, whereas it is between 80 to 98% in AD.173 Regarding the pathogenic role of CAA in AD, it has been increasingly recognized that vascular pathology, such as lacunar infarcts and WM lesions, constitutes a risk factor for AD.125,129,174 While matter hyperintensities have been described to have a similar posterior distribution as microbleeds, which predominantly appear in the occipital lobes, not only in CAA subjects but also in AD subjects.172,175 An association between microbleeds and WM lesions is supported by the same risk factor, hypertension.176 An important feature of CAA is degeneration of cells of the vascular walls. Endothelial cells and pericytes are involved in maintaining the BBB.177 Thus, degeneration of these cells may lead to a focal dysfunction of the BBB in AD. There is evidence that Aβ accumulates in pericapillary and perieratinal drainage pathways,178 and is cleared from the interstitial fluid to vessels by passing through the BBB.27,56 A compromised BBB may be required for deposition of Aβ both in the brain parenchyma and in blood vessel walls. Aβ originating from plasma may play a role in Aβ deposition in CAA when BBB integrity is compromised by other factors such as hypertension, atherosclerosis, and stroke.56 Soluble Aβ within the brain may also have toxic effects on vascular endothelium adversely affecting BBB 27,179 In fact, increasing Aβ levels may affect the BBB before pathological changes, such as CAA and Aβ plaques appear. On the other hand, Aβ produced by neurons may be the primary source of senile plaques, since neuronal Aβ may not be transported by the interstitial fluid drainage towards the periphery along the perivascular spaces.170,180 High frequency of neuritic plaques and AD pathological criteria (CERAD, Braak, and NIA-Reagan-Institute) associated with increased CAA might be clinicalopathological evidence of impaired Aβ drainage in cerebellar vessels.125,181 Massive deposits of Aβ in capillaries and precapillaries cause obliteration of the lumen, degeneration of endothelium, and basal lamina that lead to ischemia.170 Eventual damage of blood vessel walls results in microhemorrhages, impairment of brain perfusion, and strokes.

Cerebral amyloid angiopathy is thought to be implicated in AD-related vascular dysfunction in another way. A study showed that the structural and functional disruption of smooth muscle cells in the walls of leptomeningial vessels was affected by Aβ deposition in transgenic mouse without muscle cell loss. The disruption of smooth muscle cell organization interfered with the ability of the vessel to respond appropriately to both an endothelial-dependent vasodilator (acetylcholine [ACh]) and an endothelial-independent vasodilator (sodium nitroprusside).182 These results suggest that disorganized smooth muscle cells may contribute to vascular dysfunction, lead to cerebral hypoperfusion, and eventually result in impaired brain function. To summarize: on the one hand the amyloid cascade is driven by ischemia, and small vessel disease impairs amyloid clearance thereby facilitating its deposition both as interstitial plaques and along vessels. In turn, amyloid is a vascular toxin, and when it also accumulates around arteriolar walls, it can cause both ischemia and hemorrhage. It is both response to vascular risk factors and itself a vascular risk factor, which can lead to ischemic and hemorrhagic stroke and also dementia.

Aβ Imaging in Vivo

The development of PET has allowed us to understand differences of CBF, glucose metabolism, and neurotransmitter function in the brain between normal subjects and AD patients. However, sensitivity, specificity, and positive and negative predictive values may not be sufficient, though new quantitative analysis techniques can identify a network of regions of glucose hypometabolism that form AD “signatures”, which can be calculated for an individual patient and may have clinical utility.183,184 PET Aβ imaging for early detection of AD pathology and for evaluation of the efficacy of antiamyloid therapies has been developed in the past decade. [11C]-2-(4'-methylamino-phenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1, or [11C] Pittsburgh compound B or PIB) and [11C]-4-N-methylamino-4'-hydroxystilbene ([11C][SB-13] have been reported as Aβ detecting radiotracers in AD patients (Figure 3).24,26,185 Since the half-life of [11C]-labeled ligands is short (20.4 min), [18F]-labeled ligands with a longer half-life (109.7 min) are being developed for clinical use in the majority of institutions that lack a cyclotron.186 There are three radioligands, [18F]AH110690 (flutemetamol),187 [18F]BAY94-9172 (florbetaben),188 and [18F]AV-45 (florbetapir),189 which perform comparably to [11C]PIB.23 The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is now utilizing [18F]AV-45 so that participating sites can have an access to Aβ PET imaging without a cyclotron. (http://www.adni-info.org/Home.aspx) Florbetapir is furthest along in its development189,190 and recently achieved FDA labelling for clinical use in detecting cerebral amyloid deposition.191 The development of these radiotracers was based on Thiофлавин T, which detects Aβ with a β-sheet structure. Hence these ligands also label fibrillar amyloid in plaques or vessels. This also means that it may be difficult to detect preclinical neuropathology of AD in its earliest phases as these radioligands cannot detect LMW Aβ or soluble Aβ species.

High magnetic field strength magnetic resonance imaging (MRI) can detect Aβ deposition in transgenic mice,192 but to our knowledge, only one report has claimed to show putative Aβ plaques using 7 Tesla MRI in vivo human brain,193 in a small series ten AD subjects, ten age-matched normal controls, and ten young normal subjects. The putative plaques were seen in the parietal cortex in all cases of AD and in two out of ten age-matched controls.

Postmortem neuropathologic examinations have shown senile plaques and NFTs in the brains of subjects with very early AD, MCI, and even normal aging, and accumulation of Aβ may begin in the brains of AD and Down’s syndrome patients 10 to 40 years prior to the onset of clinical dementia symptoms.157,194 Aβ deposition progresses by a stepwise involvement of
Thal and colleagues have found a hierarchical pattern of Aβ deposition in the brains of AD subjects with and without dementia.\(^{196}\) They found that Aβ deposition begins in the whole neocortex (Phase 1) and expands into deeper brain tissues such as the allocortex (Phase 2), the diencephalic nuclei (Phase 3), the brainstem nuclei (Phase 4), and finally the cerebellum (Phase 5). This hierarchy was also found in the brains of APP or PS1 transgenic mice.\(^{197}\) Aβ deposits become apparent before clinical symptoms appear, and clinically proven AD is a late stage of this process. They also found that AD-related pathology cases (clinically not demented but pathology positive) show less expansion of Aβ-deposition than demented AD cases, but more than normal cases. This evidence shows that once patients progress to MCI or very mild dementia such as a Clinical Dementia Rating scale score of 0.5, the pathological changes are already severe, and conversely that as their symptoms progress further, the AD pathology is already severe without much further progression. This underlines the importance of preclinical detection of AD pathology using Aβ PET imaging. Indeed, Aβ pathology has been detected using PET imaging in MCI subjects.\(^{46,198}\) However, MCI is still an equivocal heterogeneous group, and a PET study showed subjects with and without detectable Aβ pathology.\(^{198}\) Because more than one third of older persons with MCI developed AD during an average follow-up period of about five years,\(^{45}\) non-invasive preclinical Aβ imaging with the combination of MRI/computed tomography has the possibility to discriminate a MCI-AD progressive group from a MCI-AD non-progressive group.\(^{199,200}\) The cumulative evidence of follow-up studies in MCI (mostly amnestic) and AD subjects using \([\text{11C}]\)PIB, \([\text{18F}]\)AH110690, \([\text{18F}]\)BAY94-9172, and \([\text{18F}]\)AV-45 showed a cognitive decline in amyloid positive MCI subjects.\(^{201}\) Villain et al has just reported that both PIB-positive and -negative subjects showed a significant increase in Aβ deposition, with this increase being significantly higher in PIB-positive individuals.\(^{202}\) Together, Aβ-positivity on PET appears to be a good predictor of progression from MCI to AD. Aβ imaging also would make it possible to recognize preclinical phases of AD, and to determine the extent of Aβ pathology distribution in demented patients. The most important role of \textit{in vivo} Aβ imaging will likely be in conjunction with the development of several new classes of antiamyloid therapies, which have entered the clinical trial stage (see the following section). It may improve the efficacy of Aβ therapies by providing an important surrogate outcome, namely reduction of amyloid burden.\(^{203}\)

**Figure 3**: \([\text{11C}]\)SB-13 PET data in a 77-year-old mild Alzheimer’s disease patient (left) versus a 74-year-old age-matched healthy comparison subject (right). The Aβ binding potential (Ichise noninvasive model \(R_v (k_f/k_p)^2\)) is increased in the frontal and posterior temporal-inferior parietal association cortices in the Alzheimer’s disease patient.

There are many approaches to treatment of AD. So far, the only approved treatments aim to slow decline of behavioural and cognitive function.\(^{204}\) The agents are cholinesterase inhibitors or the nicotinic agonist donepezil, the NMDA receptor antagonist memantine, or the NMDA receptor N-methyl-D-aspartate antagonist riluzole. However, treatment with these agents is not effective in all cases, and the effects are modest. However, a combination of treatment with a cholinesterase inhibitor and a NMDA receptor antagonist, especially during the early stages of dementia, may provide greater benefits than either treatment alone.\(^{205}\) Aβ imaging also would make it possible to recognize preclinical phases of AD, and to determine the extent of Aβ pathology distribution in demented patients. The most important role of \textit{in vivo} Aβ imaging will likely be in conjunction with the development of several new classes of antiamyloid therapies, which have entered the clinical trial stage (see the following section). It may improve the efficacy of Aβ therapies by providing an important surrogate outcome, namely reduction of amyloid burden.\(^{203}\)

T2*-weighted gradient-recalled echo (GRE) imaging or susceptibility-weighted imaging has been recently used to detect CAA-associated cerebral microbleeds.\(^{174,176,204}\) Since there is no difference between Aβ in plaques and in vessel walls in terms of β-sheet structure, the utility of topographical differences in Aβ binding to discriminate between these two pathological entities has been studied. A study using \([\text{11C}]\)PIB found the occipital-to-global PIB retention was greater in CAA subjects compared to AD subjects.\(^{175}\)

**TREATMENT FOR AD LINKAGE WITH Aβ**

There are many approaches to treatment of AD. So far, the only approved treatments aim to slow decline of behavioural and cognitive function.\(^{204}\) The agents are cholinesterase inhibitors or the nicotinic agonist donepezil, the NMDA receptor antagonist memantine, or the NMDA receptor N-methyl-D-aspartate antagonist riluzole. However, treatment with these agents is not effective in all cases, and the effects are modest. However, a combination of treatment with a cholinesterase inhibitor and a NMDA receptor antagonist, especially during the early stages of dementia, may provide greater benefits than either treatment alone.\(^{205}\) Aβ imaging also would make it possible to recognize preclinical phases of AD, and to determine the extent of Aβ pathology distribution in demented patients. The most important role of \textit{in vivo} Aβ imaging will likely be in conjunction with the development of several new classes of antiamyloid therapies, which have entered the clinical trial stage (see the following section). It may improve the efficacy of Aβ therapies by providing an important surrogate outcome, namely reduction of amyloid burden.\(^{203}\)
cognitive symptoms, which includes acetylcholine esterase inhibitors (AChEIs: tacrine, donepezil, rivastigmine, galantamine) and the N-methyl-D-aspartate receptor antagonist memantine. These drugs provide modest symptomatic relief with evidence of some benefit at different stages of severity, though randomized controlled studies to determine longer-term benefit are very difficult to do, so the objective evidence base is slim. Other approaches that have been tried unsuccessfully include NSAIDs and vascular risk reduction medications such as antihypertensives and cholesterol-lowering agents (e.g., statins), vitamins (e.g., vitamin E and C), and hormones such as estrogen, testosterone, and insulin. Since some aspects of preclinical neuropathological initiation of AD are understood, researchers have been investigating specific treatments targeting key toxic misfolded proteins seen in AD at autopsy, namely Aβ and hyperphosphorylated tau, the main component of NFT. Because Aβ increase is thought to constitute the earliest change in the preclinical AD brain, a huge effort is currently underway to alter Aβ formation or clearance.

Aβ modification therapies are classified into therapeutics that target amyloid production, aggregation, and/or degradation. Some of them are now being tested in ongoing clinical trials. It has been suggested that AChEIs may stimulate the non-amyloidogenic α-secretase cleavage of APP. BACE inhibitors include TAK-070 and BMS has one in development. Gamma-secretase inhibitors include: LY450139, nonpeptidic isocoumarin compounds (JLK inhibitors) now discreet, STI571 (Gleevec), and NSAIDs. The γ-secretase modulator R-flurbiprofen looked promising in a phase II trial, but failed in phase III. Amyloid aggregation targeting therapies by antifibrillation include the glycosaminoglycan mimetic NC-531 (Alzhemed), PBT-2, PPI-1019, and TTP-448. The Phase II Alzhemed trial showed reduction of CSF Aβ42 and stabilization of cognitive function in mild AD. However, the phase III trial failed to show efficacy (http://www.bellushealth.com/en/newsroom/?rkey=1506228356&view=96347-2&Start=0&htm=0).

An oral deaggregating agent by McLaurin and colleagues is a cyclohexanehetoxilo stereoisomer or scyllo-inositol, which blocks the accumulation of Aβ oligomers, and reduces AD-like behavioral deficits, AD-like neuropathology, and mortality in a transgenic mouse model of AD. Because this drug is able to alter Aβ pathology even after the symptoms appear, it may be useful not only in preclinical AD subjects but also in AD patients. A phase II trial was performed for this drug in mild to moderate AD. No clinical significance was shown, but there were some promising trends for some clinical outcomes and CSF amyloid levels in exploratory analysis.

Immunization is another Aβ modification therapy option that has been studied in both transgenic mice and AD patients. Although immunization succeeded in modulating cognitive problems and reduced Aβ plaques in APP transgenic mice, the studies using immunization with Aβ42 (AN1792) in AD patients had to be terminated prematurely owing to brain hemorrhage and/or meningoencephalitis. Pathological evidence of the post-immunization patients showed that, although there was no effect on the frequency and severity of CAA per se, hemorrhages could clearly be attributed to amyloid-laden blood vessels, and bleeding only occurred in brain areas affected by CAA. Cerebral amyloid angiopathy is therefore assumed to be a contraindication to Aβ immunization and screening for this prior to immunization therapy might improve results. The AN1792 trial in AD patients revealed decreased brain plaque burden at autopsy. However, there was no evidence for improvement of survival or severity of dementia even though some treatment responders showed some improvement in memory testing. A gantenerumab Phase II trial showed some efficacy in removing Aβ from the brain parenchyma in a dose dependent manner.

Passive immunization with a humanized recombinant Aβ monoclonal antibody directed against the N terminus of Aβ (AAB-001 or Bapineuzumab) is also under investigation and has entered a phase III clinical trial (http://clinicaltrials.gov/ct2/show/NCT00574132?term=Bapineuzumab&rank=1). There are also some other ongoing Phase II-III immunization trials underway (Refer to Clinicaltrials.gov). For further detail in the immunotherapy in AD and clinical trials, please see a Delrieu’s review article and Townsend’s review article.

Also new consensus MRI guidelines have been developed to determine eligibility and for monitoring patients for clinical trials of anti-amyloid therapies, and eventually for clinical use, should this approach reach approval for clinical use. Specifically, Fluid Attenuated Inversion Recovery imaging (FLAIR) to detect vasogenic edema and T2*-weighted gradient echo (GRE) to detect microbleeds are required at baseline and for safety monitoring as described in Sperling et al, 2011.

Conclusions

Considerable progress has been made in AD-related research. However, it is, as yet, unclear what underlies the association between vascular risk factors and AD. We know that sporadic AD is a multifactorial disorder at old age, and vascular pathology contributes to or causes the dementia syndrome. The principal pathological mechanism responsible for Aβ has not yet been identified; however, substantial evidence suggests that cardiovascular risk factors and CVD-related effects are involved. We hypothesize that sporadic AD is initiated by vascular factors in early life causing brain hypoperfusion and/or inflammation, which precede the Aβ increase and aggregation, which may also cause brain hypoperfusion and Aβ drainage dysfunction, and eventually cause the neurodegenerative process. Therefore, firstly, addressing life style, and controlling vascular, i.e. AD, risk factors, is very important for primary prevention. Secondly, since Aβ already appears widespread in the brain preclinically, detecting Aβ accumulation in vivo, by applying Aβ PET imaging in the preclinical or early stages, combined with targeting Aβ reducing therapy, may be more important for secondary prevention of AD to succeed. Further investigation is needed for assessing AD and its treatment, and in order for disease modifying therapy to become clinically available.

Acknowledgments

Dr. Honjo received salary support from the Brill Chair in Neurology, University of Toronto. Dr. Black’s research has been supported by the Canadian Institutes of Health Research (Grant #13129), the Heart and Stroke Foundation Canada, the Alzheimer’s Association, US, Alzheimer Society of Canada, National Institute of Health, and Canadian Stroke Network. Dr.
Verhoeff’s research has been supported by the Alzheimer Society of Canada, the Alzheimer Society of Saskatchewan, the Alzheimer’s Association, the Canadian Institutes of Health Research, and the Scottish Rite Charitable Foundation of Canada.

REFERENCES


